Video

Dr. Goede on the Results from the Phase III CLL11 Trial

Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.

Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.

The CLL11 trial evaluated obinutuzumab (GA101) plus chlorambucil or rituximab plus chlorambucil versus chlorambucil alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities.

Researchers found that the combination of obinutuzumab and chlorambucil prolonged progression-free survival significantly compared with chlorambucil alone. The most important piece of this finding, Goede notes, is the hazard ratio (0.14), which signifies an 86% reduction in risk of progressing with CLL in these patients. The trial also found that the hazard ratio for rituximab and chlorambucil compared with chlorambucil alone was 0.32.

Goede says that obinutuzumab and rituximab cannot be compared head-to-head with this data alone.

<<< View more from the 2013 ASCO Annual Meeting

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity